In December 2025, the FDA approved a once-daily pill version of Wegovy
Phase 1 (Weeks 1 to 2): 0.25 mg subcutaneous injection once daily, morning on empty stomach Phase 2 (Weeks 3 to 6): Maintain 0.25 mg or increase to 0.5 mg based on response and tolerance Phase 3 (Weeks 7 to 8): Continue or begin taper depending on symptom improvement Maintenance: Consider cycling 4 weeks on, 2 weeks off for long-term management Oral dosing requires higher amounts to compensate for bioavailability differences
2% glutathione, vitamin C, and kojic acid are added
While research is still evolving, many patients and peptide enthusiasts report meaningful improvements in recovery, inflammation, appearance, resilience, and overall quality of life
Andrology 8 , 903914 (2020)